U.S. Markets closed

IntelliCell BioSciences, Inc. (SVFC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00010.0000 (0.0000%)
At close: 1:26PM EDT
People also watch
ILIVLATFFFFCAEGYBMSN

IntelliCell BioSciences, Inc.

460 Park Avenue
17th Floor
New York, NY 10022
United States
212-249-3050
http://www.intellicellbiosciences.com

Sector
Industry
Full Time Employees6

Key Executives

NameTitlePayExercisedAge
Dr. Steven A. Victor M.D.Chairman and Chief Exec. Officer290kN/A65
Mr. John Huber IIIInterim Chief Financial OfficerN/AN/AN/A
Mr. Leonard A. MazurInterim Chief Operating Officer and DirectorN/AN/A71
Ms. Anna RhodesExec. VP of OperationsN/AN/AN/A
Ms. Sarah R. YoungDirector of Quality AssuranceN/AN/AN/A
Amounts are as of December 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

IntelliCell BioSciences, Inc. operates as a regenerative medicine company in the United States. It develops and commercializes regenerative medicine using adult autologous stromal vascular fraction cells derived from the blood vessels in adipose tissue. The company’s products are intended to treat various clinical conditions, such as aesthetic conditions, orthopedic and sports injuries, and pain, as well as cardiac, gastrointestinal, periodontal, and autistic disorders. It also focuses on undertaking clinical studies in partnership with universities and hospitals for osteoarthritis, gum regeneration, non-healing diabetic ulcers, multiple sclerosis, cartilage regeneration, tendon repair, facial lines and wrinkles, chronic migraine headache, bone regeneration, and hair regeneration indications. In addition, the company is involved in sourcing, selling, and distributing laboratory equipment and supplies, which are used in tissue processing activities. It also licenses its products in Canada, Australia, New Zealand, and Thailand. The company has a collaboration agreement with Hielscher Ultrasonics to develop closed processing system for cell therapy manufacturing. IntelliCell BioSciences, Inc. is based in New York, New York.

Corporate Governance

IntelliCell BioSciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.